MedPath

DUAKLIR PRESSAIR

These highlights do not include all the information needed to use DUAKLIR PRESSAIR safely and effectively. See full prescribing information for DUAKLIR PRESSAIR.DUAKLIR PRESSAIR (aclidinium bromide and formoterol fumarate) inhalation powder, for oral inhalationInitial U.S. Approval: 2019

Approved
Approval ID

8fdb44a3-4fe3-451c-b18f-d458c04fe7eb

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 25, 2022

Manufacturers
FDA

AstraZeneca Pharmaceuticals LP

DUNS: 054743190

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

aclidinium bromide and formoterol fumarate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0310-0900
Application NumberNDA210595
Product Classification
M
Marketing Category
C73594
G
Generic Name
aclidinium bromide and formoterol fumarate
Product Specifications
Route of AdministrationRESPIRATORY (INHALATION)
Effective DateJanuary 25, 2022
FDA Product Classification

INGREDIENTS (3)

FORMOTEROL FUMARATEActive
Quantity: 12 ug in 1 1
Code: W34SHF8J2K
Classification: ACTIB
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
ACLIDINIUM BROMIDEActive
Quantity: 400 ug in 1 1
Code: UQW7UF9N91
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DUAKLIR PRESSAIR - FDA Drug Approval Details